GlassScriptPhysician profile
Saif Rehman
NPI 1831185875
$3,043.68
in general payments reported to CMS, 2019-2025
30 companies · $880 in 2025
The $880 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $69.64 · 2021: $267 · 2022: $257 · 2023: $545 · 2024: $636 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $443.29 | 2019-2025 | |
| Pfizer INC. | $277.26 | 2020-2025 | |
| Abbvie INC. | $245.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.27 | 2019-2023 | Ninlaro |
| Merck Sharp & Dohme LLC | $209.68 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $198.78 | 2020-2025 | Padcev, Vyloy |
| Jazz Pharmaceuticals INC. | $175.10 | 2021-2025 | Zepzelca |
| Regeneron Healthcare Solutions, INC. | $107.82 | 2021-2024 | Libtayo |
| Lilly USA, LLC | $104.75 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $102.05 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Janssen Biotech, INC. | $93.60 | 2023-2025 | Rybrevant, Darzalex, Talvey |
| Vifor Pharma, INC. | $92.46 | 2019 | |
| Amgen INC. | $82.23 | 2019-2023 | Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $68.24 | 2024-2025 | Enhertu, Imfinzi |
| Genentech USA, INC. | $65.27 | 2019-2025 | Itovebi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.56 | 2020-2025 | Opdivo |
| Aveo Pharmaceuticals, INC. | $58.48 | 2023-2024 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $54.55 | 2021-2023 | Imbruvica |
| Seagen INC. | $49.61 | 2021-2023 | Tukysa |
| Glaxosmithkline, LLC. | $49.14 | 2021-2022 | |
| Genzyme Corporation | $42.66 | 2024-2025 | |
| Array Biopharma INC | $37.30 | 2023-2025 | Mektovi, Xalkori, Braftovi |
| Genetix Biotherapeutics INC | $33.85 | 2025 | Lyfgenia |
| Gilead Sciences, INC. | $32.70 | 2021-2023 | |
| Beone Medicines USA, INC. | $25.12 | 2025 | Brukinsa |
| Genmab U.S., INC. | $25.00 | 2024 | Tivdak |
| Daiichi Sankyo INC. | $18.05 | 2025 | Enhertu |
| Epizyme, INC. | $18.00 | 2021 | |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.